Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 3
2005 5
2006 3
2008 3
2009 2
2010 3
2011 4
2012 4
2013 1
2014 1
2016 4
2017 9
2018 3
2019 4
2020 3
2021 2
2022 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Michallet AS, Letestu R, Le Garff-Tavernier M, Campos L, Ticchioni M, Dilhuydy MS, Morisset S, Rouille V, Mahé B, Laribi K, Villemagne B, Ferrant E, Tournilhac O, Delmer A, Molina L, Leblond V, Tomowiak C, de Guibert S, Orsini-Piocelle F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan-Graczyk M, Vilque JP, Schleinitz TA, Cymbalista F, Leprêtre S, Lévy V, Nguyen-Khac F, Feugier P. Michallet AS, et al. Among authors: campos l. Blood Adv. 2023 Aug 8;7(15):3936-3945. doi: 10.1182/bloodadvances.2022009594. Blood Adv. 2023. PMID: 37026799 Free PMC article. Clinical Trial.
Heat shock proteins and acute leukemias.
Thomas X, Campos L, Le QH, Guyotat D. Thomas X, et al. Among authors: campos l. Hematology. 2005 Jun;10(3):225-35. doi: 10.1080/10245330500093120. Hematology. 2005. PMID: 16019471 Review.
Potential Role of OCT4 in Leukemogenesis.
Picot T, Kesr S, Wu Y, Aanei CM, Flandrin-Gresta P, Tondeur S, Tavernier E, Wattel E, Guyotat D, Campos L. Picot T, et al. Among authors: campos l. Stem Cells Dev. 2017 Nov 15;26(22):1637-1647. doi: 10.1089/scd.2017.0134. Epub 2017 Oct 16. Stem Cells Dev. 2017. PMID: 28911263
[Focal adhesion kinase (FAK), a multifunctional protein].
Cornillon J, Campos L, Guyotat D. Cornillon J, et al. Among authors: campos l. Med Sci (Paris). 2003 Jun-Jul;19(6-7):743-52. doi: 10.1051/medsci/20031967743. Med Sci (Paris). 2003. PMID: 12942446 Free article. Review. French.
Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients.
Chapuis N, Ibrahimi N, Belmondo T, Goulvestre C, Berger AE, Mariaggi AA, Andrieu M, Chenevier-Gobeaux C, Bayle A, Campos L, Cheurfa C, Chocron R, Diehl JL, Doumenc B, Duchemin J, Duprat M, François F, Gendron N, Mirault T, Pène F, Philippe A, Pommeret F, Sanchez O, Smadja DM, Szwebel TA, Silvin A, Ginhoux F, Lacroix L, Jules-Clément G, Rapeteramana S, Mavier C, Steller L, Perniconi B, André F, Drubay D, Fontenay M, Hüe S, Paul S, Solary E. Chapuis N, et al. Among authors: campos l. EBioMedicine. 2022 Jun;80:104077. doi: 10.1016/j.ebiom.2022.104077. Epub 2022 May 26. EBioMedicine. 2022. PMID: 35644124 Free PMC article.
Immunophenotypic clustering of myelodysplastic syndromes.
Maynadié M, Picard F, Husson B, Chatelain B, Cornet Y, Le Roux G, Campos L, Dromelet A, Lepelley P, Jouault H, Imbert M, Rosenwadj M, Vergé V, Bissières P, Raphaël M, Béné MC, Feuillard J; Groupe d'Etude Immunologique des Leucémies (GEIL). Maynadié M, et al. Among authors: campos l. Blood. 2002 Oct 1;100(7):2349-56. doi: 10.1182/blood-2002-01-0230. Blood. 2002. PMID: 12239142 Free article.
Expression of embryonic stem cell markers in acute myeloid leukemia.
Picot T, Aanei CM, Fayard A, Flandrin-Gresta P, Tondeur S, Gouttenoire M, Tavernier-Tardy E, Wattel E, Guyotat D, Campos L. Picot T, et al. Among authors: campos l. Tumour Biol. 2017 Jul;39(7):1010428317716629. doi: 10.1177/1010428317716629. Tumour Biol. 2017. PMID: 28718379 Free article.
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
Letestu R, Dahmani A, Boubaya M, Baseggio L, Campos L, Chatelain B, Debliquis A, Drénou B, Jacob MC, Legac E, Le Garff-Tavernier M, Lhoumeau AC, Quiney C, Robillard N, Ticchioni M, Aanei C, Katsahian S, Delepine R, Vaudaux S, Rouillé V, Béné MC, Dartigeas C, Van Den Neste E, Leprêtre S, Feugier P, Cartron G, Leblond V, Lévy V, Cymbalista F; French Innovative Leukemia Organization (FILO). Letestu R, et al. Among authors: campos l. Leukemia. 2021 Jun;35(6):1597-1609. doi: 10.1038/s41375-020-01009-z. Epub 2020 Sep 15. Leukemia. 2021. PMID: 32934355
55 results